Medidata Solutions

Cloud-based solutions for clinical trials

New York City, New York, United States

About Medidata Solutions

Medidata Solutions offers cloud-based solutions for managing clinical trials in the life sciences industry, serving pharmaceutical, biotech, and medical device companies, as well as academic institutions. Their main products include Rave EDC for electronic data capture, eCOA for electronic clinical outcome assessments, and ePRO for electronic patient-reported outcomes, all designed to enhance the efficiency and accuracy of clinical trials. Medidata differentiates itself from competitors by combining advanced technology with deep data insights, helping clients bring new treatments to market more quickly and cost-effectively. The company's goal is to improve patient outcomes through effective clinical trial management while promoting diversity and inclusion.

New York City, New YorkHeadquarters
1999Year Founded
$21.7MTotal Funding
ACQUISITIONCompany Stage
Enterprise Software, Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Unlimited Paid Time Off
Health & Wellness
Professional Development
Work/Life Balance
Maternity & Paternity Leave

Risks

Increased competition from emerging AI-driven platforms threatens Medidata's market share.
Data privacy concerns and regulatory scrutiny could impact Medidata's operations.
The MedTech sector's funding challenges may limit Medidata's innovation and growth.

Differentiation

Medidata offers a comprehensive suite of cloud-based solutions for clinical trials.
The company leverages AI and advanced analytics to enhance trial efficiency and accuracy.
Medidata's platform integrates data from various sources, accelerating decision-making in trials.

Upsides

Medidata's partnership with Bristol Myers Squibb enhances clinical research and patient outcomes.
The launch of Medidata Clinical Data Studio modernizes data management in clinical trials.
Medidata's Patient Payments solution streamlines reimbursements, improving patient experience in trials.

Funding

Total raised$21.72 M
Latest valuation$5.80 B
StageACQUISITION
ACQUISITION
5/31/2019
$5.8 K
$5.80 B
$1
LATE VC
5/31/2004
$20
$100.00 M
SERIES C
2/28/2003
$1
$5.40 M